Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; prescription drug payment reform; and pharmaceutical supply chain.
2025 · 4th Quarter (Oct 1 - Dec 31)
PURDUE PHARMA LLP
Filed by CAPITOL HILL CONSULTING GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Termination
- Posted
- Jan 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- CAPITOL HILL CONSULTING GROUP
- Client
- PURDUE PHARMA LLP
- Filing UUID
- 1fd56ed7-1a1f-4d9f-85a8-1ea0a214b6b6
- Termination date
- Dec 31, 2025
Literal source text
Lobbying issues and bill citations
Monitored congressional efforts around the SACKLER Act.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.